Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)
Status:
Not yet recruiting
Trial end date:
2027-05-15
Target enrollment:
Participant gender:
Summary
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab
combined with oral chemotherapy or endocrine therapy in patients with HER-2 positive stage I
breast cancer.